FDA Challenges WHOOP Over Blood Pressure Insights
In July 2025 WHOOP received an FDA warning over its Blood Pressure Insights (BPI) feature, and the dispute culminated in new FDA wellness guidance issued January 6, 2026. The article reviews the FDA's arguments—'inherent association', language and interface concerns—and WHOOP's responses, noting ambiguous wellness exemptions and implications for wearable makers seeking to report biomarker data without medical-device classification.
Scoring Rationale
High-impact, official FDA guidance and industry analysis elevates regulatory clarity; limited novel technical breakthroughs or AI-specific implications reduce broader ML significance.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalWHOOP, There It Is: Lessons From WHOOP’s FDA Warning Letterjmir.org
